The Journal of **Rheumatology**

Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus

Juan C. Quevedo-Abeledo[1], Hiurma Sánchez-Pérez[2] (iD), Beatriz Tejera-Segura[3] (iD), Laura de Armas-Rillo[4] (iD), Soledad Ojeda[1], Celia Erausquin[1], Miguel Á. González-Gay[5] (iD), and Iván Ferraz-Amaro[2] (iD)

ABSTRACT. **Objective.** Since insulin resistance (IR) is highly prevalent in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), we aimed to determine whether differences in IR exist between the two conditions.
Methods. We conducted a cross-sectional study comprising 413 subjects without diabetes (186 with SLE and 227 with RA). Glucose, insulin, and C-peptide serum levels, as well as IR by the homeostatic model assessment (HOMA2) were studied. A multivariable regression analysis was performed to evaluate the differences in IR indexes between patients with SLE and RA, as well as to determine if IR risk factors or disease-related characteristics are differentially associated with IR in both populations.
Results. The insulin:C-peptide molar ratio was upregulated in patients with RA compared to patients with SLE (β 0.009, 95% CI 0.005–0.014, $P < 0.001$) after multivariable analysis. HOMA2 indexes related to insulin sensitivity (HOMA2-%S) were found to be lower (β –27, 95% CI –46 to –9, $P = 0.004$) and β cell function (HOMA2-%B) showed higher IR indexes (β 38, 95% CI 23–52, $P < 0.001$) in RA than in SLE patients after multivariable analysis. Patients with RA more often fulfilled the definition of IR than those with SLE (OR 2.15, 95% CI 1.25–3.69, $P = 0.005$). The size effect of IR factors on IR indexes was found to be equal in both diseases.
Conclusion. IR sensitivity is lower and β cell function is higher in RA than in SLE patients. The fact that traditional IR factors have an equal effect on IR in both SLE and RA supports the contention that these differences are related to the diseases themselves.

Key Indexing Terms: insulin resistance, rheumatoid arthritis, systemic lupus erythematosus

Insulin resistance (IR) can be broadly defined as a subnormal biological response to normal insulin concentrations. By this definition, it may pertain to many biological actions of insulin in many tissues of the body[1]. Typically, in clinical practice, IR refers to a state in which a given concentration of insulin is associated with a subnormal glucose response. It more commonly occurs in association with obesity but may be the result of a number of different underlying causes that include induced stress (due to hormones such as cortisol), medications [e.g., glucocorticoids (GC)], pregnancy, insulin antibodies, and/or genetic defects in insulin-signaling pathways. Long-term consequences of IR include the development of type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease[2].

In the last decade, it has become increasingly evident that

the presence of inflammation constitutes a major component of IR. Studies on IR have revealed a clear association between the chronic activation of proinflammatory signaling pathways and decreased insulin sensitivity[3]. For example, elevated levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 and IL-8 have all been reported in IR states[4,5,6,7]. In this regard, the administration of anti–TNF-α and anti–IL-6 receptor therapy yielded a dramatic reduction of IR in individuals with rheumatoid arthritis (RA) without diabetes[6,7].

RA and systemic lupus erythematosus (SLE), both recognized inflammatory diseases, have been widely associated with IR[8,9]. The mechanisms that lead to IR in patients with SLE and RA seem to differ from those implicated in the general population or T2DM[10]. This may explain why the strong influence of traditional factors associated with IR in healthy individuals appears to have less effect on patients with RA[11]. In addition, disease damage over time has also been found to contribute to IR in an independent manner in patients with SLE[9].

Although SLE and RA share autoimmune mechanisms, they are completely different disorders that have their own unique pathogenic pathways. Most studies regarding IR in SLE and RA were performed using healthy controls as comparators. The aim of the present study was to determine if there were differences in the prevalence of IR between SLE and RA. We have also aimed to determine the effect of traditional IR risk factors on the development of IR in both SLE and RA, and whether some disease features relate to IR in a different manner depending on the disease.

MATERIALS AND METHODS

Study participants. The main hypothesis of this work was to study if IR varies between patients with SLE and RA. If this were the case, since IR is a feature highly related to CV risk and subclinical atherosclerosis, we could identify if one disease is more predisposed to CV disease than the other. This was a cross-sectional study that included 413 individuals (186 patients with SLE and 227 with RA). All were 18 years of age or older and were included in the study if they fulfilled ≥ 4 American College of Rheumatology (ACR) 1997 classification criteria for SLE[12] and the 2010 ACR/European League Against Rheumatism Classification Criteria for RA[13]. Although treatment with anti–TNF-α therapies has demonstrated improved insulin sensitivity[14,15], patients with RA undergoing this therapy were not excluded from the present study. Likewise, patients taking prednisone or its equivalent at a dose ≤ 10 mg/day were not excluded. However, none of the patients included in this study were on glucose-lowering drugs or insulin therapy. Patients with diabetes mellitus (DM) were excluded. In this regard, all patients had blood glucose of < 7 mmol/L. Patients were also excluded if they had a history of cancer or any other chronic disease, evidence of active infection, or a glomerular filtration rate < 60 ml/min/1.73 m². A CONSORT flow diagram[16] including enrollment and dropouts is shown in Figure 1. The study protocol was approved by the institutional review committee at Hospital Universitario de Canarias and Hospital Doctor Negrín, both in Spain, and all subjects provided informed written consent (Approval Number 2015/84).

Data collection. Patients were assessed for CV risk factors and medication. Hypertension was defined as a systolic or diastolic blood pressure > 140 or 90 mmHg, respectively. SLE disease activity and damage were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000[17] and the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI)[18], respectively. Disease severity was measured as well, using the Katz Index[19]. In patients with RA, disease activity was measured using the Disease

Activity Score in 28 joints (DAS28)[20], while disease disability was determined using the Multidimensional Health Assessment Questionnaire (MDHAQ)[21]. Clinical Disease Activity Index[22] and Simple Disease Activity Index[23] scores for RA disease activity were calculated as previously described.

Assessments. Fasting serum samples were collected and frozen at −80 °C until analysis of circulating lipids, glucose, insulin, and C-peptide was carried out. Cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were measured using an enzymatic colorimetric assay (Roche Diagnostics). Cholesterol levels ranged from 0.08 to 20.7 mmol/L (intraassay coefficient of variation 0.3%), triglyceride levels ranged from 4 to 1.000 mg/dL (intraassay coefficient of variation 1.8%), and HDL cholesterol levels ranged from 3 to 120 mg/dL (intraassay variation coefficient 0.9%). Low-density cholesterol was calculated using the Friedewald formula. Insulin (Architect Abbott, 2000I) and C peptide (Immulite 2000, Siemens) were determined by chemiluminescent immunometric assays. Reference values for glucose and insulin were 60–110 mg/dL and < 20 mU/mL, respectively. The homeostatic model assessment (HOMA) method was performed to determine IR. In this study, we used HOMA2, which is the updated HOMA model[24]. In our study, all IR HOMA indexes were calculated using both insulin and C peptide. In this regard, C peptide better estimates β cell function since it is a marker of secretion, while insulin data is preferable when calculating insulin sensitivity (%S) since HOMA-%S is derived from glucose disposal as a function of insulin concentration. The computer model gives a value for insulin sensitivity expressed as HOMA2-%S (where 100% is normal). HOMA2-IR (insulin resistance index) is simply the reciprocal of %S. The insulin to C-peptide ratio, which is thought to reflect hepatic insulin extraction, was also calculated. IR, as a binary variable, was defined according to HOMA2-IR ≥ 1.85 in men or > 2.36, 2.07, or 2.47 in women aged 30, 50, or 70 years, respectively, as previously described[25].

Statistical analysis. Sample size calculations were performed assuming that, as in a previous report of our group, IR was 0.15 points higher in RA patients compared to controls[10]. We expected to find similar differences between SLE and RA patients. Therefore, to obtain a power of 80% to detect differences in the contrast of the null hypothesis (no differences between SLE and RA patients) by means of a bilateral *t*-test for 2 independent samples, taking into account that the level of significance is 5% and assuming that the mean of the reference group is 1.00 units, the mean of the experimental group is 1.15 units, and the SD of both groups is 0.50 units, it will be necessary to include 220 units in the reference group (RA) and 147 units in the experimental group (SLE), totaling 367 experimental units in the study. Demographic and clinical characteristics in patients with SLE and RA were described as the mean ± SD or percentages for categorical variables. For non-normally distributed continuous variables, data were expressed as a median and IQR. Univariable differences between patients with SLE and RA were assessed through *t*-test, U Mann-Whitney, chi-square, or Fisher exact tests according to normal distribution or number of subjects. To investigate the differences in IR indexes and glucose metabolism molecules between SLE and RA patients, we constructed 3 models: (1) an unadjusted model for the univariable differences; (2) an adjusted Model 1 using those variables with a *P* value < 0.20 that had been previously identified by the differences between SLE and RA (sex, age, BMI, hypertension, and dyslipidemia); and (3) Model 2 adjusted for the same variables of model 1 plus variables related to the disease [disease duration and the use of prednisone, methotrexate (MTX), and hydroxychloroquine (HCQ)]. In this analysis, confounding factors were selected if they were related both to the independent variable and the IR indexes with a *P* value < 0.20. All the analyses used a 5% two-sided significance level and were performed using SPSS software, version 21 (IBM) and STATA software, version 15/SE (StataCorp). A *P* value < 0.05 was considered statistically significant.

RESULTS

Demographic, laboratory, and disease-related data. A total of 186 patients with SLE (mean ± SD age of 50 ± 11 yrs) and 227 RA

Figure 1. Recruitment flow chart diagram. RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.

patients (mean 52 ± 10 yrs) were included in the study. No significant difference was found in the comparison of age between both populations (*P* = 0.053). Demographic and disease-related characteristics of the participants are shown in Table 1. Neither the BMI nor the frequency of obesity differed between the patients with SLE and RA. However, waist circumference (92 ± 13 cm vs 96 ± 13 cm, *P* < 0.001) was higher in patients with RA. Traditional CV risk factors were common in both conditions. Nevertheless, only hypertension was found to be significantly different between groups, being higher in patients with SLE (38% vs 25 %, *P* = 0.004).

Regarding disease-related data, disease duration was found to be longer in SLE patients (17 ± 9 years vs 10 ± 9 years in RA, *P* < 0.001), with the current and cumulative dose of prednisone also proving higher in SLE patients. While the use of HCQ was significantly higher in SLE patients, current use of MTX or leflunomide was more common in patients with RA. Further data including disease-related scores, the laboratory features of each condition, and the use of biologic therapies are shown in Table 1.

Multivariable regression analysis of the differences in IR indexes between SLE and RA. In general, glucose homeostasis molecules were found to be significantly upregulated in patients with RA when compared to patients with SLE in the univariable analysis (Table 2). In this sense, both insulin (8.0, 5.5–16.40 vs 7.2, IQR 4.4–10.6 mU/mL, *P* = 0.032] and C-peptide serum levels (3.57 ± 2.97 vs 3.05 ± 2.65 ng/mL, *P* = 0.060) were higher in RA patients, although statistical significance was not reached for

C-peptide. Similarly, most HOMA2 indexes were different in RA when compared to SLE patients. Remarkably, HOMA2-%S was lower and HOMA2-%B–C-peptide higher in RA patients than in those with SLE. Moreover, the frequency of IR status, defined as a binary variable, was higher in RA patients than in those with SLE (25% vs 14%, *P* = 0.005; Table 2).

To assess if these differences were independent of other factors related to IR or independent of data related to the disease, we set up adjusted models (Models 1 and 2; Table 2). First, we adjusted for the classic factors associated with IR that were different in patients with SLE and RA. Afterward, we additionally included in Model 2 those variables related to both diseases that met the criteria to be considered confounding factors. Consequently, most of the differences regarding glucose homeostasis molecules and HOMA2 indexes were maintained. In this regard, although insulin and C-peptide differences were lost after multivariable analysis, the insulin:C-peptide molar ratio upregulation persisted in RA patients (β 0.009, 95% CI 0.005–0.014, *P* < 0.001). Similarly, HOMA2 indexes related to insulin sensitivity and β cell function were found to be significantly lower and higher in RA, respectively. Additionally, the OR for the presence of IR in patients with RA showed a positive relation (OR 2.15, 95% CI 1.25–3.69, *P* = 0.005) when compared to that of patients with SLE.

When patients were stratified according to prednisone intake, we observed that RA patients not taking prednisone exhibited a higher number of significant differences in glucose homeostasis molecules and IR indexes than those with SLE. In contrast, in

Table 1. Characteristics of SLE and RA patients.

	SLE, n = 186	RA, n = 227	P
Age, yrs	50 ± 11	52 ± 10	0.053
Female, n (%)	177 (95)	184 (81)	**< 0.001**
BMI, kg/m²	27 ± 5	28 ± 5	0.065
Abdominal circumference, cm	92 ± 13	96 ± 13	**< 0.001**
Cardiovascular comorbidity, n (%)			
Smoking	43 (23)	41 (18)	0.20
Diabetes	0 (0)	0 (0)	–
Hypertension	70 (38)	56 (25)	**0.004**
Obesity	46 (25)	69 (30)	0.20
Dyslipidemia[a]	114 (61)	158 (70)	0.067
Statins	45 (24)	65 (29)	0.31
Disease-related data			
CRP, mg/L	1.9 (0.9–4.9)	2.8 (1.3–5.5)	0.68
Disease duration, yrs	17 ± 9	10 ± 9	**< 0.001**
Rheumatoid factor, n (%)	20 (11)	158 (70)	**< 0.001**
ACPA, n (%)	–	141 (62)	–
Current prednisone treatment, n (%)	95 (51)	83 (37)	**0.002**
Prednisone, mg/day	6 ± 4	5 ± 3	**0.001**
Prednisone cumulative dose over 5 yrs, g	6.8 ± 4.1	5.1 ± 3.5	**0.004**
DMARD, n (%)	144 (77)	186 (82)	0.25
Hydroxychloroquine, n (%)	126 (68)	3 (1)	**< 0.001**
Methotrexate, n (%)	21 (11)	151 (67)	**< 0.001**
Leflunomide, n (%)	3 (2)	36 (16)	**< 0.001**
Salazopyrin, n (%)	–	1 (0)	–
Tofacitinib, n (%)	–	3 (1)	–
Baricitinib, n (%)	–	3 (1)	–
Mycophenolate mofetil, n (%)	15 (8)	–	–
Azathioprine, n (%)	25 (13)	–	–
Anti–TNF-α therapy, n (%)	–	36 (16)	–
Rituximab, n (%)	6 (3)	–	–
Belimumab, n (%)	3 (2)	–	–
Cyclophosphamide, n (%)	1 (1)	–	–
SLICC	1 (0–2)	–	–
SLICC ≥ 1	136 (60)	–	–
Katz Index	2 (1–3)	–	–
Katz Index ≥ 3	70 (31)	–	–
SLEDAI	2 (0–5)	–	–
SLEDAI activity[b], n (%)		–	–
No activity	73 (32)	–	–
Mild	61 (27)	–	–
Moderate	29 (13)	–	–
High or very high	13 (6)	–	–
ANA profile			
Anti-DNA positive, n (%)	96 (42)	–	–
ENA positive, n (%)	63 (28)	–	–
C3, mg/dL	96 ± 27	–	–
C4, mg/dL	17 ± 7	–	–
DAS28	–	2.22 ± 1.09	–
DAS28-CRP	–	2.50 ± 1.00	–
CDAI	–	8 (4–15)	–
SDAI	–	13 (7–20)	–
MDHAQ	–	0.625 (0.250–1.125)	–

Data represent mean ± SD or median (IQR) when data were not normally distributed. Significant *P* values are depicted in bold. [a] Dyslipidemia was defined if one of the following was present: total cholesterol > 200 mg/dL, triglycerides > 150 mg/dL, HDL cholesterol < 40 in men or < 50 mg/dL in women, or LDL cholesterol > 130 mg/dL. [b] SLEDAI categories were defined as follows: 0, no activity; 1–5, mild activity; 6–10, moderate activity, and > 10, high or very high activity. ACPA: anticitrullinated protein antibodies; ANA: antinuclear antibodies; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; DMARD: disease-modifying antirheumatic drug; ENA: extractible nuclear antibodies; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MDHAQ: Multidimensional Health Assessment Questionnaire; RA: rheumatoid arthritis; SDAI: Simple Disease Activity Index; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics/American Colleague of Rheumatology Damage Index; TNF: tumor necrosis factor.

Table 2. Multivariable regression analysis of the differences in IR indexes between SLE and RA patients.

	SLE, n = 186	RA, n = 227	P	Model 1[a] β (95% CI)[c], P	Model 2[b]
Glucose, mg/dL	100 ± 20	89 ± 18	**< 0.001**	**−12 (−16 to −9), < 0.001**	**−10 (−14 to −6), < 0.001**
Insulin, mµ/mL	7.2 (4.4–10.6)	8.0 (5.5–16.40)	**0.032**	1.6 (−0.9 to 4.1), 0.20	
C-peptide, ng/mL	3.05 ± 2.65	3.57 ± 2.97	0.060	0.19 (−0.35 to 0.74), 0.48	
Insulin:C-peptide molar ratio	0.07 ± 0.02	0.08 ± 0.03	**0.001**	**0.009 (0.005–0.014), < 0.001**	**0.009 (0.005–0.014), < 0.001**
HOMA2-%B	90 ± 49	131 ± 66	**< 0.001**	**36 (25–48), < 0.001**	**37 (26–48), < 0.001**
HOMA2-%S	130 ± 91	109 ± 80	**0.011**	−14 (−30 to 2), 0.093	**−27 (−46 to −9), 0.004**
HOMA2-IR[d]	0.95 (0.59–1.44)	1.04 (0.70–2.02)	0.058	0.17 (−0.15 to 0.49), 0.30	
HOMA2-%B–C peptide	134 ± 67	178 ± 80	**< 0.001**	**37 (23–51), < 0.001**	**38 (23–52), < 0.001**
HOMA2-%S–C peptide	71 ± 49	65 ± 43	0.17	0 (−8 to 9), 0.94	
HOMA2-IR–C peptide	1.75 (1.07–2.70)	1.86 (1.12–3.13)	0.15	0.06 (0.37–0.49), 0.78	
IR, n (%)	26 (14)	57 (25)	**0.005**	**1.94 (1.10–3.39), 0.020[e]**	**2.15 (1.25–3.69), 0.005[e]**

Values are mean ± SD or median (IQR) unless otherwise specified. Significant values are depicted in bold. [a] Model 1 was adjusted for age, sex, BMI, hypertension, and dyslipidemia. [b] Model 2 was adjusted for Model 1 + disease duration and the use of prednisone, methotrexate and hydroxychloroquine. [c] β coefficients were calculated using SLE as the reference category. [d] IR is a binary variable and refers to HOMA2-IR > rather than a specific cutoff for age or sex. [e] β were log-transformed to represent the OR. HOMA2-IR: homeostatic assessment model for insulin resistance using insulin and glucose serum levels; HOMA2%B–C peptide: homeostatic assessment model for β cell function using C peptide and glucose serum levels; HOMA2-%S: homeostatic assessment model for insulin sensitivity; IR: insulin resistance; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.

Table 3. Differences in IR indexes between SLE and RA patients stratified according to prednisone intake.

	SLE, n = 89 No Prednisone	RA, n = 144	P	SLE, n = 95 Prednisone	RA, n = 83	P
Glucose, mg/dL	98 ± 16	87 ± 17	**< 0.001**	101 ± 23	93 ± 19	**0.006**
Insulin, mµ/mL	6.6 (4.0–9.8)	7.7 (5.1–15.9)	**< 0.001**	7.6 (5.0–12.8)	9.8 (5.9–17.0)	0.66
C-peptide, ng/mL	2.45 ± 1.68	3.39 ± 2.85	**0.002**	3.61 ± 3.23	3.88 ± 3.15	0.58
Insulin:C-peptide molar ratio	0.07 ± 0.02	0.08 ± 0.03	**0.001**	0.07 ± 0.03	0.08 ± 0.02	0.12
HOMA2-%B	82 ± 37	134 ± 72	**< 0.001**	99 ± 57	125 ± 56	**0.002**
HOMA2-%S	141 ± 90	114 ± 82	**0.018**	121 ± 93	100 ± 77	0.11
HOMA2-IR	0.88 (0.52–1.30)	0.97 (0.65–2.00)	**< 0.001**	0.99 (0.67–1.69)	1.85 (1.61–1.24)	0.70
HOMA2-%B–C-peptide	119 ± 51	180 ± 85	**< 0.001**	148 ± 77	176 ± 70	**0.013**
HOMA2-%S–C-peptide	81 ± 52	70 ± 46	0.093	62 ± 45	56 ± 36	0.34
HOMA2-IR–C-peptide	1.61 (0.90–2.36)	1.67 (0.99–3.14)	**0.007**	2.07 (1.28–3.40)	1.97 (1.38–3.13)	0.70
IR[a]	7 (8)	35 (24)	**0.001**	19 (20)	22 (27)	0.30

Significant P values are depicted in bold. [a] IR refers to HOMA2-IR > cutoff for age and sex. HOMA2%B–C-peptide: homeostatic assessment model for β cell functionality using C peptide and glucose serum levels; HOMA2-IR: homeostatic assessment model for insulin resistance using insulin and glucose serum levels; HOMA2-%S: homeostatic assessment model for insulin sensitivity; IR: insulin resistance; RA: rheumatoid arthritis: SLE: systemic lupus erythematosus.

the subgroup of patients taking prednisone, only β cell function was found to be upregulated in RA patients when compared with SLE patients (Table 3).

The differential effect of classic factors associated with IR between patients with SLE and RA. The influence of classic factors associated with IR and disease-related data on glucose homeostasis molecules and IR indexes is shown in Table 4. In general, these factors were strongly associated with IR and β cell function in both diseases. Remarkably, comparisons of the size effect of these relationships between SLE and RA patients were not significant.

Similarly, C-reactive protein (CRP) serum levels and the current use of prednisone was associated with higher HOMA2-IR, albeit only in SLE patients. However, the CRP and HOMA2-IR relationships did not differ between RA and SLE patients (interaction $P = 0.62$).

DISCUSSION

Increasing awareness of the role of inflammation-induced IR in rheumatic inflammatory diseases has emerged in recent years. However, previous reports mainly focused on comparisons between individuals with these inflammatory diseases and healthy controls. Most did not address the fact that the degree of IR can vary between different inflammatory diseases. In this regard, although the influence of traditional factors associated with IR in healthy populations is similar to that observed in SLE and RA, the results of our study indicate that IR is more prevalent in patients with RA than in those with SLE.

The differences in IR between immune-mediated diseases and controls have already been explored. For this reason, we did not include controls in our study. We were interested in assessing if differences in IR between SLE and RA exist. There are few

Table 4. Differential effects of classic factors associated with IR and disease-related features on IR in patients with SLE and RA.

	HOMA2-IR			HOMA2-%B–C-peptide		
	SLE	RA	β (95% CI), P P^a	SLE	RA	P^a
Age, yrs	0.02 (−0.01–0.04), 0.14	**0.03 (0.01–0.05), 0.009**	0.66	0.71 (−0.17 to 1.58), 0.11	0.59 (−0.44 to 1.62), 0.26	–
Female, n (%)	0.17 (−0.94 to 1.28), 0.76	−0.39 (−0.94 to 0.17), 0.18	–	13 (−32 to 58), 0.57	**−33 (−60 to −6), 0.015**	0.10
BMI, kg/m²	**0.08 (0.04–0.13), < 0.001**	**0.09 (0.05–0.13), < 0.001**	0.76	**4 (2–6), < 0.001**	**5 (3–7), < 0.001**	0.68
Abdominal circumference, cm	**0.04 (0.02–0.06), < 0.001**	**0.04 (0.02–0.06), < 0.001**	0.83	**2 (1–3), < 0.001**	**2 (1–3), < 0.001**	0.84
Cardiovascular comorbidity, n (%)						
Smoking	−0.26 (−0.82 to 0.30), 0.36	0.05 (−0.52 to 0.62), 0.86	–	−17 (−40 to 6), 0.15	1 (−26 to 29), 0.92	–
Diabetes	–	–		–	–	
Hypertension	**0.73 (0.25–1.22), 0.003**	0.25 (−0.25 to 0.76), 0.33	0.18	**40 (21–59), < 0.001**	**28 (4–52), 0.023**	0.45
Obesity	**0.60 (0.05–1.14), 0.032**	**0.73 (0.26–1.20), 0.002**	0.71	**26 (3–48), 0.024**	**35 (12–58), 0.003**	0.57
Dyslipidemia	0.38 (−0.12 to 0.87), 0.14	0.22 (−0.26 to 0.69), 0.38	–	11 (−9 to 31), 0.27	**23 (0–46), 0.049**	0.45
Statins	0.35 (−0.21 to 0.91), 0.21	0.36 (−0.12 to 0.85), 0.14	–	**29 (7–52), 0.012**	**33 (10–56), 0.005**	0.36
Disease-related data						
CRP, mg/L	**0.03 (0.01–0.04), 0.005**	0.00 (−0.01 to 0.02), 0.70	0.62	**0.98 (0.26–1.69), 0.008**	0.47 (−0.18 to 1.13), 0.16	0.32
Disease duration, yrs	0.02 (−0.01 to 0.04), 0.20	−0.01 (−0.03 to 0.02), 0.59	0.20	0.27 (−0.76 to 1.31), 0.61	−0.14 (−1.36 to 1.08), 0.82	0.60
Current prednisone use, n (%)	**0.67 (0.19–1.93), 0.006**	0.20 (−0.26 to 0.65), 0.40	0.16	**28 (9–48), 0.004**	−4 (−26 to 18), 0.71	0.27
Prednisone, mg/day	−0.00 (−0.13 to 0.12), 0.91	0.09 (−0.03 to 0.21), 0.13	0.27	3 (−1 to 7), 0.18	2 (−3 to 7), 0.42	0.80
Prednisone cumulative 5 yrs, g	−0.0 (−0.12 to 0.12), 0.96	0.07 (−0.03 to 0.17), 0.18	0.37	3 (−2 to 7), 0.22	2 (−2 to 6), 0.38	0.83

Significant values are depicted in bold. ^a P value for the interaction factor in the comparison of β between SLE and RA patients. CRP: C-reactive protein; HOMA2-%B–C peptide: homeostatic assessment model for β cell functionality using C peptide and glucose serum levels; HOMA2-IR: homeostatic assessment model for insulin resistance using insulin and glucose serum levels; IR: insulin resistance; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.

studies comparing IR in patients with SLE versus those with RA. In a report that included 15 patients with SLE, 15 with RA, and 15 with systemic sclerosis (SSc), patients with SLE exhibited higher HOMA2-%B than patients with RA and SSc[26]. However, this study failed to show any differences in HOMA2-IR between groups. The study did not include a multivariable analysis, likely due to the small sample size. HOMA2-IR was found to be higher in RA compared to SLE patients in another report that included 103 patients with SLE and 124 patients with RA[27]. However, this difference was not adjusted for covariables and analysis of β cell function through assessments of C-peptide serum levels was not performed. Besides, in a study of 100 women with SLE and 98 with RA, IR was significantly higher in women with RA compared to those with SLE[28]. This difference remained significant after adjustment for BMI and GC. However, no adjustment was performed for factors related to the disease and no males were included in this study. In contrast, in another study of 95 RA and 57 SLE female patients that used a surrogate index of IR (triglycerides and glucose index), no differences were found between the diseases[29]. Therefore, we believe that the high number of subjects included in our study and the inclusion of multivariable regression analysis are sufficiently powerful enough factors to render our results conclusive.

In our study, the differences in IR between patients with SLE and RA were mainly detected in those patients who had not undergone GC treatment. We believe that the absence of differences in patients currently taking prednisone stems from the fact that these patients experienced deleterious effects of GC and, therefore, experienced upregulated IR. The mechanisms by which GC cause IR are multifactorial and include the augmentation of hepatic gluconeogenesis, the inhibition of glucose uptake in adipose tissue, and the alteration of receptor and postreceptor functions[30]. When we performed our analyses using the entire sample, the differences between SLE and RA in IR indexes were adjusted for prednisone intake. In this regard, we realize that the differences between SLE and RA were greater in patients without prednisone, which supports the concept that these differences cannot be simply attributed to its use.

The insulin to C-peptide ratio is < 1 in subjects without DM. This reflects the fact that a large fraction of endogenous insulin is cleared by the liver whereas C-peptide, which is cleared primarily by the kidneys and has a lower metabolic clearance rate than insulin, bypasses the liver, thereby avoiding any extraction by hepatocytes. For this reason, the ratio of insulin to C-peptide has been assumed to reflect hepatic insulin extraction. A number of studies have suggested that reduced hepatic extraction of insulin is a major factor in the pathogenesis underlying the hyperinsulinemia observed in IR states[31]. In our study, this ratio was higher in RA than in SLE patients after multivariable analysis. According to our results, insulin clearance may be amplified in patients with RA compared to those with SLE.

Classic factors associated with IR in the general population were also associated with HOMA2 indexes in our cohort of SLE and RA patients. In fact, an association of disease duration and current prednisone use with IR was found in our series of SLE patients. However, the size effect of these factors on IR was not higher in SLE than in RA. Although BMI has been reported to exert a greater influence on IR in SLE than in RA[27], we could find no such differences in our series.

The relation of disease activity and damage with IR in SLE and RA has been previously analyzed in reports of our group. In this sense, for example, the SDI has been independently associated with IR in SLE[9]. However, disease activity composite scores such as the DAS28 failed to demonstrate associations with IR. We believe that it may probably be due to the fact that these scores in RA only captured activity in a transversal manner. On the other hand, the potential antidiabetic properties of HCQ are well known, and this drug is more commonly prescribed to SLE than RA patients in Spain[32]. We feel that this effect that could have some influence on patients with SLE was also controlled through multivariable analysis adjustment. However, HCQ was not related to IR in a previous report in patients with SLE[9].

Metaanalysis data indicated that IR increases the risk of incident CV disease in the general population[33]. Inflammation may worsen IR and impair pancreatic β cell function[34]. Consequently, an increased risk of premature CV death was observed in patients with SLE and RA. In this sense, a metaanalysis of 24 observational studies comprising 111,758 patients concluded that the risk of coronary artery disease mortality was 59% higher in patients with RA than in the general population[35]. Similarly, a systematic review that included 28 studies showed that the risk of CV disease among SLE patients was at least double that of the general population[36]. However, the incidence and prevalence of CV disease in patients with SLE and RA depended on specific manifestations of the disease, the population evaluated, and/or the screening and diagnostic methods utilized. For this reason, it is difficult to establish whether CV disease is more prevalent in one disease or the other. The fact that IR was higher in RA than SLE in our population may be indicative of the higher CV risk borne by patients with RA.

In our study, there were no differences in CRP between SLE and RA patients. Additionally, CRP was related to HOMA2-IR, albeit only in SLE patients. When the size effect of CRP on IR or β cell function was compared between the 2 diseases, no significant differences were found. Therefore, we contend that CRP was not responsible for the differences in IR observed between SLE and RA.

Statin intake was high in our patients with SLE and RA, being used in a quarter of patients. It is known that statins can affect glucose metabolism and that they may influence the development of DM in nondiabetics or affect glycemic control in patients with existing DM[37]. Nevertheless, since statin use was the same in both diseases in our study, we believe that its effect on IR was similar in SLE and RA. Therefore, the higher IR found in RA patients could not be attributed to statins.

We acknowledge the limitation that patients were not sex-matched in this study. Nevertheless, the size effect of this difference was found to be small (95% vs 81% of females in analyzed SLE and RA cohorts, respectively). Moreover, identical results were reported regardless of matching, when multivariable regression analysis was applied in epidemiological studies[38].

We therefore believe that the multivariable analysis procedure performed in our study was able to handle confounding situations in the analysis regarding individuals not matched by sex.

Adipokines may influence IR in patients with SLE and RA. However, the role of adipokines on IR was not assessed in our study. This could be a potential limitation of our study. However, the mechanisms by which cytokines or adipokines affect IR in the healthy population are still far from being fully understood.

In conclusion, IR is higher in RA than in SLE patients. This cannot be explained by factors classically associated with IR or disease-related data like CRP, disease duration, or the use of prednisone. Specific mechanisms underlying each disease may be responsible for these differences. Identification of these mechanisms will lead to a greater understanding of each disease.

REFERENCES

1. Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
2. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994;94:1714-21.
3. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105.
4. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29:777-822.
5. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
6. Gonzales-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:373-9.
7. Castañeda S, Remuzgo-Martínez S, López-Mejías R, Genre F, Calvo-Alén J, Llorente I, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol 2019;37:465-73.
8. Ferraz-Amaro I, García-Dopico JA, Medina-Vega L, González-Gay MA, Díaz-González F. Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients. Arthritis Res Ther 2013;15:R17.
9. Sánchez-Pérez H, Tejera-Segura B, de Vera-González A, González-Delgado A, Olmos JM, Hernández JL, et al. Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clin Exp Rheumatol 2017;35:885-892.
10. Ferraz-Amaro I, López-Mejias R, Tejera-Segura B, de Vera-González AM, Ubilla B, Olmos JM, et al. Amylin in the insulin resistance of patients with rheumatoid arthritis. Clin Exp Rheumatol 2018;36:421-427.
11. Tejera-Segura B, López-Mejías R, de Vera-González AM, Jiménez-Sosa A, Olmos JM, Hernández JL, et al. Relationship between insulin sensitivity and β-cell secretion in nondiabetic subjects with rheumatoid arthritis. J Rheumatol 2019;46:229-36.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
14. Miranda-Filloy JA, Llorca J, Carnero-López B, González-Juanatey C, Blanco R, González-Gay MA. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:850-5.
15. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6.
16. Barbour V, Bhui K, Chescheir N, Clavien PA, Diener MK, Glasziou P, et al. CONSORT statement for randomized trials of nonpharmacologic treatments: A 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med 2017;167:40-7.
17. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
18. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
19. Katz JD, Senegal JL, Rivest C, Goulet JR, Rothfield N. A Simple severity of disease index for systemic lupus erythematosus. Lupus 1993;2:119-23.
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
21. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999;42:2220-30.
22. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8.
23. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
24. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
25. Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord BMC Endocr Disord 2013;13:47.
26. Kotyla PJ. Insulin resistance varies across connective tissue diseases patients: comparison between rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Clin Exp Rheumatol 2019;37:14.
27. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12.
28. Santos MJ, Vinagre F, Canas Da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of Caucasian female patients. Clin Exp Rheumatol 2011;29:470-6.

29. Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L, Espinel-Bermudez MC, Garcia-Benavides L, Perez-Guerrero E, et al. Fasting triglycerides and glucose index: A useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus. Diabetol Metab Syndr 2019;11:95.

30. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.

31. Polidori DC, Bergman RN, Chung ST, Sumner AE. Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data. Diabetes 2016;65:1556-64.

32. Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J Diabetes Res 2020;2020:5214751.

33. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.

34. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006;54:2765-75.

35. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.

36. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77-95.

37. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61.

38. Faresjö T, Faresjö Å. To match or not to match in epidemiological studies—same outcome but less power. Int J Environ Res Public Health 2010;7:325-32.